IDE modifications reg
This article was originally published in The Gray Sheet
Executive Summary
Publication of a final version of the rule could be held up until after the Nov. 21 deadline stipulated by the FDA Modernization Act because the Office of Management and Budget has determined that the rule is "significant" and worthy of OMB's review, FDAers say. OMB has 90 days from June 17 to review the rule before it can be issued as a proposed rule in the Federal Register. The rule, which will spell out which modifications may be made to an investigational device exemption product or protocol without FDA notification, is one of eight rules and guidances that the agency's device center had planned for release by September ("The Gray Sheet" June 29, p. 7)
You may also be interested in...
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.